Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glucose metabolism in patients with psoriasis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Cause-specific mortality in patients with psoriasis and psoriatic arthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Development of HiSQOL: A Hidradenitis Suppurativa-Specific Quality of Life Instrument

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Increased Suicide Risk in Patients with Hidradenitis Suppurativa

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

An inappropriate immunological response to an unknown antigen has been suggested to play a role in the pathogenesis of hidradenitis suppurativa (HS). Studies have identified elevated levels of several proinflammatory cytokines, including interleukin (IL)-17A and tumour necrosis factor-α, nominating these as possible therapeutic targets.1 Secukinumab is an IL-17A monoclonal antibody, which binds to IL-17A and inhibits the cytokine interaction with the IL-17 receptors, inhibiting the inflammatory cascade. Here we report a case of a 47-year-old man, with Hurley stage III lesions on the neck, axillae, breasts, genital skin and buttocks, who had experienced only temporary benefit from different medical treatments over several years. After 12 weeks of treatment with secukinumab, the number of lesions reported by the patient within the period of the last 4 weeks was reduced from 23 to seven, his pain visual analogue scale (VAS) score was reduced from 5 to 3 and pain/utility/handicap VAS score was reduced from 7 to 4. These results may be taken to imply that IL-17 blockade could provide a possible therapeutic approach in the treatment of HS.

OriginalsprogEngelsk
TidsskriftBritish Journal of Dermatology
Vol/bind179
Udgave nummer1
Sider (fra-til)182-185
Antal sider4
ISSN0007-0963
DOI
StatusUdgivet - jul. 2018

ID: 56062075